The known immune response in PD with co-pathology incidence is integrated, highlighting synergistic interactions between α-syn, tau and Aβ and how this promotes a distinct neuroinflammatory response leading to severe neuronal loss and cognitive symptoms.
Abstract
Co-expression of tau and amyloid-beta with α-syn pathology is shown in over 50% of Parkinson’s Disease postmortem brains, and these patients present with enhanced cognitive decline and disease phenotype. This review integrates the known immune response in PD with co-pathology incidence, highlighting synergistic interactions between α-syn, tau and Aβ and how this promotes a distinct neuroinflammatory response leading to severe neuronal loss and cognitive symptoms. Based on this, we support the need for combinatorial therapeutic strategies to address this debilitating, yet common factor of disease.
Investigation of anti-α -synuclein immunotherapy as a potential disease-modifying strategy for PD found no evidence of delay in motor progression and exploratory studies suggested potential clinical activity.
A. Boehringer, L. Kalia, B. Bloem et al.· Journal of Parkinson's Disea...· 0 citations
Cognitive decline in Parkinson's disease (PD), progressing from mild cognitive impairment (PD-MCI) to severe dementia (PD-D), is a debilitating core feature driven by complex neuropathological interactions. While α-synuclein accumulation is the disease's hallmark, co-pathologies involving amyloid-β and tau, alongside c...
Daniel Oppermann Peixoto, J. Gasparotto, O. Ojo et al.· Ageing Research Reviews· 0 citations
This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction,...
Desh Deepak Singh· Current Neuropharmacology· 0 citations
Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.
This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.
Priya, Radhika Mittal, Jyotirmoy Banerjee et al.· International review of neur...· 0 citations
Despite decades of intensive research, progress in treating late-onset Alzheimer's disease remains limited. A central problem may be conceptual: Alzheimer's disease may not be a single disease, but a heterogeneous syndrome arising from differing combinations of aging, genetic susceptibility, vascular injury, metabolic...
A. Korczyn· Journal of Alzheimer's Disea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
